← Eichor
Condition: Pancreatic Cancer Stage Iii Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Pancreatic Cancer Stage Iii

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Polymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer
Phase 3 · 2 location(s) · Shanghai Yizhong Pharmaceutical Co., Ltd. · NCT06752811Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
Phase 3 · 118 location(s) · SWOG Cancer Research Network · NCT06807437Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Wi
Phase 3 · 274 location(s) · SWOG Cancer Research Network · NCT06998940An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancr
Phase 3 · 2 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT05884255Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors
Phase 1/Phase 2 · 3 location(s) · National Cancer Institute (NCI) · NCT05053971CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With
Phase 2 · 1 location(s) · Northwestern University · NCT05733000Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherap
Phase 3 · 28 location(s) · Gruppo Oncologico del Nord-Ovest · NCT06897644Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Chang
Phase 1 · 18 location(s) · National Cancer Institute (NCI) · NCT05372614Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC
Phase 3 · 1 location(s) · Sahlgrenska University Hospital · NCT06714604Targeted Pathway Inhibition in Patients With Pancreatic Cancer
EARLY_Phase 1 · 1 location(s) · OHSU Knight Cancer Institute · NCT04005690Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Tr
Phase 3 · 4 location(s) · M.D. Anderson Cancer Center · NCT06593431A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positi
Phase 3 · 1 location(s) · Innovent Biologics (Suzhou) Co. Ltd. · NCT07066098Radiotherapy With GX Regimen as Adjuvant Therapy for High-risk Patients Following Pancreatic Cancer Surgery
Phase 3 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07632118A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and
Phase 2/Phase 3 · 2 location(s) · Hutchmed · NCT06361888TR-002 for the Treatment of Advanced Unresectable Metastatic Solid Tumors Unresectable or Metastatic, Refractory Pancrea
Phase 1 · 1 location(s) · University of California, Davis · NCT07189195The Role of MicroRNA in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer
Phase N/A · 1 location(s) · Nuvance Health · NCT04406831A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer
Phase 3 · 3 location(s) · Akeso · NCT06953999Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders
Phase N/A · 3 location(s) · Mayo Clinic · NCT00830557Improved Recovery by Iron Following Surgery With Blood Loss, the IRIS-trial
Phase 3 · 1 location(s) · Jon Unosson · NCT05744219A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metasta
Phase 2 · 109 location(s) · Sameek Roychowdhury · NCT06906562A Tailored, Web-based Program (COMPASS) to Improve Exercise and Dietary Changes in Stage I-III Pancreatic Cancer Patient
NA · 1 location(s) · OHSU Knight Cancer Institute · NCT07651358Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer
Phase 3 · 1 location(s) · GC Cell Corporation · NCT04969731Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
Phase 1 · 10 location(s) · National Cancer Institute (NCI) · NCT05687123Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable
Phase 2 · 1 location(s) · Emory University · NCT06423326Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objective
NA · 1 location(s) · M.D. Anderson Cancer Center · NCT01365169Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Phase 2 · 448 location(s) · SWOG Cancer Research Network · NCT05040360Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
NA · 1 location(s) · Cedars-Sinai Medical Center · NCT04907643Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally A
Phase 1/Phase 2 · 44 location(s) · National Cancer Institute (NCI) · NCT04172532Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Phase 3 · 322 location(s) · NRG Oncology · NCT06958328Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer
Phase 3 · 1 location(s) · Genfleet Therapeutics (Shanghai) Inc. · NCT07262567
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.